Introduction
Although most patients with hypertension are treated initially with monotherapy, 1 only one out of two successfully control their blood pressure (BP) with monotherapy. 2 Thus, many patients will require combination therapy, most rationally, with the addition of a second drug from a different pharmacological class.
The diuretic hydrochlorothiazide (HCTZ), although commonly used as initial monotherapy for hypertension, is associated with several dose-related adverse metabolic effects including increases in glucose, cholesterol, uric acid, and calcium and decreases in magnesium and potassium. 3 Irbesartan is a potent angiotensin II receptor antagonist with high affinity for the AT 1 receptor subtype. 4 Because irbesartan has a complementary mechanism of action to HCTZ, 4, 5 its use in combination may allow the use of a lower dose of HCTZ. Irbesartan may also blunt some of the adverse metabolic effects of HCTZ, particularly hypokalaemia. ؊15.7 mm Hg (n ‫؍‬ 948), and ؊20.6/؊15.6 mm Hg (n ‫؍‬ 898), respectively. From months 2 to 12, normalisation rates (trough SeDBP Ͻ90 mm Hg) ranged from 75-85% and total responder rates (normalised or у10 mm Hg trough SeDBP reduction) ranged from 81-91%, while target BP was achieved in 65-75% of patients. At all time-points, most patients (у87%) were receiving irbesartan/HCTZ alone. Eighty-two patients (7.5%) discontinued the study due to adverse events, with half of these events considered unrelated to study medication. There were no reports of serious adverse events related to study medication. Long-term therapy with irbesartan/HCTZ is safe, well tolerated, and maintains normalised BP in Ͼ80% of patients.
In clinical trials, irbesartan monotherapy has demonstrated dose-related lowering of BP in hypertensive patients 6, 7 with placebo-like tolerability. 8 Shortterm studies of irbesartan/HCTZ have shown no pharmacokinetic interaction 9 and greater reductions in BP than either antihypertensive agent administered alone. 10 Controlled studies have shown that irbesartan/HCTZ, is well tolerated. 6, [9] [10] [11] [12] The primary objective of this study was to evaluate the long-term safety, tolerability, and antihypertensive effects of irbesartan/HCTZ (alone or with adjunctive antihypertensive medications) in patients with mild-to-moderate hypertension.
Materials and methods

Study design
Two similar open-label extension studies were conducted at 93 centres in Argentina, Brazil, Mexico, and the United States. Each of these two studies was preceded by a 4-to 5-week, single-blind, placebo lead-in period, followed by a double-blind period in which patients were randomised to receive parallel treatment with several doses of irbesartan alone, HCTZ alone, irbesartan/HCTZ, or placebo. During the double-blind period of Study 1, irbesartan doses ranged from 37.5-300 mg and HCTZ doses ranged from 6.25-25 mg. During the double-blind period of Study 2, the irbesartan doses were 75 mg and 150 mg and the HCTZ dose was 12.5 mg. Each 1-year, open-label extension study began immediately after the double-blind period. In each study, the starting dose was irbesartan 75 mg/HCTZ 12.5 mg once daily. If target BP (Ͻ140/Ͻ90 mm Hg) was not achieved, the dose was titrated sequentially at 2-to 4-week intervals to irbesartan 150 mg/HCTZ 12.5 mg, then to irbesartan 300 mg/HCTZ 25 mg. If necessary, atenolol (25-50-100 mg) and/or nifedipine sustained release (30-60 mg) could be added and titrated as necessary to achieve target BP. Once target BP was achieved, the treatment regimen was continued for the remainder of the open-label extensions. Patients who did not achieve target BP were discontinued.
Patients
For enrolment into both double-blind studies, men and postmenopausal or surgically sterile women у18 years of age with mild-to-moderate essential hypertension (seated diastolic BP [SeDBP] 95-110 mm Hg) were eligible. Exclusion criteria for the open-label extension phase included: (1) SeDBP Ͼ110 mm Hg or seated systolic BP (SeSBP) Ͼ200 mm Hg; (2) significant cardiovascular, neurologic, psychiatric, endocrinologic, pulmonary, renal, autoimmune, haematologic, or gastrointestinal disease, a malignancy, or any other diseases considered by the investigator to make participation in the study not in the best interests of the patient; (3) need for concomitant medications that might interfere with the assessment of efficacy or safety (eg, drugs known to affect BP, prolonged courses of non-steroidal antiinflammatory drugs); and (4) allergy to HCTZ or any sulpha-containing medication. Patients completing double-blind therapy and who continued to satisfy all of the exclusion criteria listed above were given the option of continuing into the 1-year, open-label extensions. All patients provided written informed consent, and the open-label extensions were approved by the relevant local institutional review boards and conducted according to Good Clinical Practice guidelines.
Blood pressure measurements
Trough (24 ± 3 h after ingestion of study medication) seated BP was measured using a mercury sphygmomanometer at all clinic visits (months 2, 4, 6, 8, and 12). Three measurements were taken at least 1-min apart after the patient rested for 10 min in the seated position. If the SeDBP readings were not within 8 mm Hg of each other, an additional two readings were obtained and incorporated into the calculated mean. Heart rate was determined by pulse count after the last BP reading.
Safety
Reported adverse events were recorded at all clinic visits. Blood and urine samples were obtained for standard laboratory tests at initiation of open-label therapy, within 4 weeks following initiation or upward titration of doses, and every 4 months thereafter. A physical examination and 12-lead electrocardiogram were performed at entry and at the end of the open-label period.
Statistical methods
All patient data from both protocols were pooled for this analysis. Quantitative demographic and baseline (ie, as determined at entry to the double-blind period) characteristics were summarised and qualitative data were tabulated. No hypothesis testing was performed. Efficacy variables were summarised using the available data from all patients at each time-point. Normalisation rates (trough SeDBP Ͻ90 mm Hg), total responder rates (normalised or у10 mm Hg trough SeDBP reduction from baseline) and the percentage of patients who achieved target BP (Ͻ140/Ͻ90 mm Hg) were summarised. Adverse events were summarised according to treatment prescribed at the time of the event. Mean changes from baseline (ie, prior to receiving double-blind drug) laboratory values were also summarised.
Results
Demographic and baseline characteristics
To be eligible for the open-label extensions, patients had to complete double-blind therapy, continue to satisfy all exclusion criteria, and be willing to participate. Of the 1098 individuals enrolled into the open-label extensions of the two studies (representing 73% of all patients completing doubleblind therapy), 1095 received at least one dose of open-label study medication and had at least one follow-up visit. One hundred and ninety-eight patients discontinued open-label therapy: the most common reasons for discontinuation were adverse events (7.5%), site, sponsor, or patient request (5.8%), lost to follow-up (2.3%), and poor compliance (1%). Poor BP control accounted for Ͻ1% of discontinuations.
The majority of patients were men (58%), White (76%), and Ͻ65 years of age (84%), and most (79%) had a SeDBP Ͻ104 mm Hg. Mean age was 54 years, and mean seated Bp was 152/100 mm Hg (Table 1) . Demographic characteristics were similar between the two protocols, except that in Study 1, the racial composition was 86% White, 8% Black, and 6% other races, and in Study 2 was 69% White, 11% Black, and 20% other races.
Changes in trough seated blood pressure
Clinically significant reductions from baseline trough SeDBP and trough SeSBP were achieved during the first clinic visit (2 months) and maintained until the end of the study period (12 months). Mean changes in trough SeSBP/SeDBP at months 2, 6, and 12 were −19.1/−14.2 mm Hg (n = 941), −20.7/−15.7 mm Hg (n = 948), and −20.6/−15.6 mm Hg (n = 898), respectively ( Figure 1 ). Heart rate remained stable throughout.
Therapeutic response
For most patients BP control was achieved by 2 months and was sustained throughout (Figure 2 ). Normalisation rates (trough SeDBP Ͻ90 mm Hg) were 75%, 85%, and 83% at months 2, 6, and 12, respectively. Corresponding total responder rates (normalised or у10 mm Hg trough SeDBP reduction from baseline) were 81%, 91%, and 90%. Target BP (Ͻ140/Ͻ90 mm Hg) was achieved in 65%, 75%, and 70% of patients at months 2, 6, and 12, respectively.
Distribution of dose regimens
Throughout both open-label extensions, most patients required only irbesartan/HCTZ, without the need for additional antihypertensive agents (Table 2) . From months 2 through 12, at least 87% of patients were receiving irbesartan/HCTZ alone.
Subgroup analyses
Analyses of the therapeutic responses according to gender, race, and age were performed. At month 12, similar reductions in trough SeDBP were achieved in men and women. A slightly higher percentage of women were normalised compared with men (87% vs 80%), even though more women were receiving irbesartan/HCTZ alone (90% vs 84% for men). Similar mean reductions in trough SeDBP and SeSBP and response rates were achieved among the various races (White, Black, and other) at month 12. Only 10% to 15% of the patients in each racial subgroup required adjunctive antihypertensive therapy in addition to irbesartan/HCTZ. Compared with patients who were Ͻ65 years of age, patients who were у65 years of age had a higher mean baseline SeSBP (161 mm Hg vs 150 mm Hg) and a slightly larger mean decrease in trough SeSBP at month 12 (24 mm Hg vs 20 mm Hg). In contrast, both groups had the same mean baseline SeDBP (100 mm Hg) and similar decreases in trough SeDBP at month 12 (Ͻ65 years, 15 mm Hg vs у65 years, 16 mm Hg). Although SeDBP normalisation rates at month 12 were similar in these two groups (Ͻ65 years, 83% vs у65 years, 84%), a smaller percentage of patients у65 years achieved both systolic and diastolic target BP at month 12 (55% vs 73%). The percentage of patients у65 years and Ͻ65 years receiving irbesartan/HCTZ without adjunctive antihypertensive therapy were similar (85% vs 87%).
Safety and tolerability
The mean duration of exposure to irbesartan (±HCTZ or other adjunctive therapy) was 325 days, giving a total exposure of 975 patient-years. A total of 82 patients (7.5%) discontinued the study due to adverse events. The most frequent causes were fatigue (0.8%), rash (0.5%), atrial rhythm disturbances (0.4%), dizziness (0.4%), and increased liver enzymes (0.4%). The adverse events resulting in discontinuation were considered unrelated to study medication in 41 of these 82 patients (50%). A total of 75 serious adverse events were reported by 58 patients (5.3%), none of which was considered by the investigator to be related to study medication. Two patients died: one during openlabel therapy (motor vehicle accident) and one post study (cardiac arrest); neither death was considered by the investigators to be attributed to study medication. The most frequently occurring serious adverse events were myocardial infarction, angina pectoris, and invasive cardiac procedures (three patients each) which is not unexpected for this population.
During open-label therapy, 794 patients (72%) reported one or more adverse events. The most common events were musculoskeletal pain, upper respiratory infection, headache, and fatigue (Table 3) . No relationship to dose was observed. Orthostatic dizziness was reported in 3.2% of patients. One patient (irbesartan 75 mg/HCTZ 12.5 mg) experienced tongue and throat swelling that was reported as angioedema and judged unrelated to study medication.
Clinically important abnormalities in laboratory values were rarely seen. A total of 11 patients (1%) discontinued due to laboratory adverse events, the most common cause being increased liver enzymes or bilirubin (0.4%). Elevated creatine kinase, glucose, potassium, and triglycerides led to discontinuation of one patient each. Mean changes in total cholesterol, low-density and high-density lipoprotein cholesterol, glucose, potassium, sodium, calcium, magnesium, and uric acid concentrations were not clinically significant. There were also no clinically significant changes in physical examination or electrocardiogram findings. 
Discussion
For many hypertensive patients, BP is not adequately controlled by monotherapy. A combination of two antihypertensive drugs with a complementary mechanism of action (eg, a diuretic plus angiotensin II receptor antagonist) has the potential to improve efficacy. 1, 2 Furthermore, the use of lower doses of diuretics, as is usually the case with combination therapy, can result in improved tolerability. 1, 2 This may be particularly important for diuretics, which are often associated with doserelated side effects. 3, 13 Improvements in efficacy and tolerability may lead to increased patient compliance and thus improve long-term management of hypertension. 3 The present clinical trials demonstrate that longterm therapy of irbesartan (75-300 mg)/HCTZ (р25 mg), alone or with adjunctive antihypertensive medications, is safe, well-tolerated, and effective in patients with mild-to-moderate hypertension. Furthermore, adverse events were not dose-related. Although previous double-blind, placebo-controlled clinical trials of irbesartan/HCTZ were of short duration, 6,9-11 they were not intended to assess longterm efficacy or safety. The present 1-year, openlabel extensions of two double-blind, randomised, placebo-controlled trials allowed for titration and addition of adjunctive antihypertensive agents when necessary. This study design is also useful in that it mimics the conditions found in actual clinical practice.
The long-term efficacy results in the present report are in agreement with those of short-term trials with irbesartan/HCTZ. 6, [9] [10] [11] [12] In long-term use, BP was well controlled with titration of once-daily irbesartan/HCTZ followed, if necessary, by the addition and titration of adjunctive antihypertensive agents. BP was normalised (trough SeDBP Ͻ90 mm Hg) in 75% of patients at month 2 and in 83% of patients at month 12. The total responder rate (normalised or у10 mm Hg trough SeDBP reduction from baseline) increased from 81% at month 2 to 90% at month 12. The target BP of Ͻ140/Ͻ90 mm Hg was achieved in 70% of the patients at month 12. About 90% of patients whose BP was normalised or who achieved target BP (Ͻ140/Ͻ90 mm Hg) were receiving irbesartan/HCTZ alone, ie, without the need for further antihypertensive agents. Poor BP control accounted for only 1% of all patients entering the study.
Less than one-third of patients receiving angiotensin-converting enzyme (ACE) inhibitors, calcium channel blockers, beta-blockers, or diuretics continue the same therapy for more than 1 year.
14 No significant long-term tolerability concerns were associated with irbesartan/HCTZ (even with adjunctive antihypertensive agents), which confirms the excellent short-term safety profile of the combination. 6, [9] [10] [11] [12] Although the incidence of withdrawal due to adverse events was higher during the openlabel extensions (7.5%) than during the doubleblind phases of the studies (3.6%), this is likely due to the longer duration of observation or possibly due to the presence of additional antihypertensive agents. No relationship between dose and incidence of adverse events was observed, consistent with the short-term experience with irbesartan monotherapy. 8 The results of this study demonstrate that longterm therapy with irbesartan/HCTZ (alone or with adjunctive antihypertensive medications) in patients with mild-to-moderate hypertension is safe, well tolerated, and maintains normalised BP in at least 80% of patients.
